Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out what makes OCGN worth a Buy.

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options.

Shares of Ocugen Inc. OCGN advanced 2.65% to $1.16 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.94% to 6,033.11 ...

Shares of Ocugen Inc. OCGN slipped 2.75% to $1.06 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.08% to ...

MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a $330 million market cap biotechnology company whose stock has surged over 33% in the past six months, announced Monday that the U.S. Food and Drug ...

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced ...

Ocugen announced FDA clearance for a pivotal trial of OCU410ST gene therapy for Stargardt disease, addressing significant medical need.

Carisma Therapeutics and OrthoCellix announced a merger to develop NeoCart®, a cartilage repair technology, aiming for Nasdaq listing.

Serious about understanding the stock market? Whether you're investing for yourself or eyeing a finance career, knowing how it works is the first step.